yaz plus tablets film-coated
bayer weimar gmbh & co. kg - pink tablet-drospirenone, ethinyl estradiol, levomefolate (levomefolate calcium); light orange tablet-levomefolate (levomefolate calcium) - tablets film-coated - pink tablet-3mg+ 0,02mg+ 0,451mg
yaz plus tablets film-coated
bayer weimar gmbh & co. kg - pink tablet-drospirenone, ethinyl estradiol, levomefolate (levomefolate calcium); light orange tablet-levomefolate (levomefolate calcium) - tablets film-coated - pink tablet-3mg+ 0,02mg+ 0,451mg
vzole voriconazole 200 mg film-coated tablets blister pack
arrotex pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; maize starch; croscarmellose sodium; povidone; silicon dioxide; magnesium stearate; titanium dioxide; hypromellose; triacetin - voriconazole is indicated for treatment of the following fungal infections:invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
vzole voriconazole 50 mg film-coated tablets blister pack
arrotex pharmaceuticals pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; maize starch; croscarmellose sodium; povidone; silicon dioxide; magnesium stearate; titanium dioxide; hypromellose; triacetin - voriconazole is indicated for treatment of the following fungal infections:invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
reactine chewable tablets 5 mg tablet (chewable)
mcneil consumer healthcare division of johnson & johnson inc - cetirizine hydrochloride - tablet (chewable) - 5mg - cetirizine hydrochloride 5mg - second generation antihistamines
reactine chewable tablets 10 mg tablet (chewable)
mcneil consumer healthcare division of johnson & johnson inc - cetirizine hydrochloride - tablet (chewable) - 10mg - cetirizine hydrochloride 10mg - second generation antihistamines
vfend voriconazole 50mg tablet blister pack
pfizer australia pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
vfend voriconazole 200mg tablet blister pack
pfizer australia pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
mavenclad 10 mg tablets
merck serono ltd - cladribine - tablets - cladribine 10 mg - cladribine - mavenclad 10mg tablets is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (ms) as defined by clinical or imaging features
metadex xr 20 mg
k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - capsules extended release - dexmethylphenidate hydrochloride 20 mg - dexmethylphenidate - metadex xr extended-release capsules are a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults.